Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Roche Holding (OTC:RHHBY)

Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'

Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% weight-loss over 42 weeks.

Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Roche Holding (OTC:RHHBY)

Roche Group AG’s (OTC:RHHBY) obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading treatments from Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY). Genentech on Thursday shared topline results from the Phase 2 ZUPREME-1 trial evaluating petrelintide versus placebo in 493 obese participants (mean BMI of 37 kg/m²). In …

Obesity drug trial failure sends biotech firm’s shares into record decline

The drug helped patients to lose weight, but ultimately paled in comparison to rival treatments

Roche and Zealand’s Phase II obesity trial divides analyst opinion

Some analysts question if petrelintide’s efficacy could impact uptake and sales, while others tout its tolerability and combination potential.The post Roche and Zealand’s Phase II obesity trial divides analyst opinion appeared first on Clinical Trials Arena.

Dansk pharmaceutical company stock drops after weight loss data - The Copenhagen Post

Shares of the Danish pharmaceutical company Zealand Pharma fell sharply after the company released new data for its weight loss drug Petrilintid. By 10 a.m., the stock was down 30 percent. The results from a phase 2 study, published Thursday evening, showed weight loss of up to 10.7 percent of body weight after 42 weeks. […]